Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical Donor-Derived B Lymphocyte Infusions in ALS
NCT07838389Phase 1Not yet recruiting
- Start
- Sep 2027
- Primary completion
- Jan 2030
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in amyotrophic lateral sclerosis (ALS). Primary endpoints: Infusion associated adverse events of special interest and Evidence of host rejection of infused cells. Planned start Sep 2027; status: not yet recruiting.
02
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07838389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07838389.